Delavirdine gets the green light.
Vazquez
E
E
D002986:Clinical Trials as Topic; D020008:Delavirdine; D017277:Drug Approval; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D019562:Viral Load
D007211:Indoles; D010879:Piperazines; D018894:Reverse Transcriptase Inhibitors; D020008:Delavirdine